<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Data Brief</journal-id><journal-id journal-id-type="iso-abbrev">Data Brief</journal-id><journal-title-group><journal-title>Data in Brief</journal-title></journal-title-group><issn pub-type="epub">2352-3409</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28664173</article-id><article-id pub-id-type="pmc">5480823</article-id><article-id pub-id-type="publisher-id">S2352-3409(17)30248-2</article-id><article-id pub-id-type="doi">10.1016/j.dib.2017.06.004</article-id><article-categories><subj-group subj-group-type="heading"><subject>Data Article</subject></subj-group></article-categories><title-group><article-title>Dietary amino acid intakes associated with a low-phenylalanine diet combined with amino acid medical foods and glycomacropeptide medical foods and neuropsychological outcomes in subjects with phenylketonuria</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Stroup</surname><given-names>Bridget M.</given-names></name><xref rid="aff0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Murali</surname><given-names>Sangita G.</given-names></name><xref rid="aff0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Nair</surname><given-names>Nivedita</given-names></name><xref rid="aff0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Sawin</surname><given-names>Emily A.</given-names></name><xref rid="aff0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Rohr</surname><given-names>Fran</given-names></name><xref rid="aff0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Levy</surname><given-names>Harvey L.</given-names></name><xref rid="aff0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Ney</surname><given-names>Denise M.</given-names></name><email>ney@nutrisci.wisc.edu</email><xref rid="aff0005" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#x0204e;</xref></contrib></contrib-group><aff id="aff0005"><label>a</label>Department of Nutritional Sciences, University of Wisconsin-Madison, WI, United States</aff><aff id="aff0010"><label>b</label>Division of Genetics and Genomics, Boston Children&#x005f3;s Hospital, Harvard Medical School, Boston, MA, United States</aff><author-notes><corresp id="cor1"><label>&#x0204e;</label>Correspondence to: University of Wisconsin-Madison, Department of Nutritional Sciences, 1415 Linden Drive, Madison, WI 53706 Fax: +1 608262 5860. <email>ney@nutrisci.wisc.edu</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>07</day><month>6</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>8</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>07</day><month>6</month><year>2017</year></pub-date><volume>13</volume><fpage>377</fpage><lpage>384</lpage><history><date date-type="received"><day>6</day><month>4</month><year>2017</year></date><date date-type="rev-recd"><day>10</day><month>5</month><year>2017</year></date><date date-type="accepted"><day>1</day><month>6</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 The Authors</copyright-statement><copyright-year>2017</copyright-year><license license-type="CC BY" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract id="ab0010"><p>This article provides original data on median dietary intake of 18 amino acids from amino acid medical foods, glycomacropeptide medical foods, and natural foods based on 3-day food records obtained from subjects with phenylketonuria who consumed low-phenylalanine diets in combination with amino acid medical foods and glycomacropeptide medical foods for 3 weeks each in a crossover design. The sample size of 30 subjects included 20 subjects with classical phenylketonuria and 10 with a milder or variant form of phenylketonuria. Results are presented for the Delis-Kaplan Executive Function System and the Cambridge Neuropsychological Test Automated Battery; the tests were administered at the end of each 3-week dietary treatment with amino acid medical foods and glycomacropeptide medical foods. The data are supplemental to our clinical trial, entitled &#x0201c;Glycomacropetide for nutritional management of phenylketonuria: a randomized, controlled, crossover trial, 2016 (1) and &#x0201c;Metabolomic changes demonstrate reduced bioavailability of tyrosine and altered metabolism of tryptophan via the kynurenine pathway with ingestion of medical foods in phenylketonuria, 2017 (2). This data has been made public and has utility to clinicians and researchers due to the following: 1) This provides the first comprehensive report of typical intakes of 18 amino acids from natural foods, as well as amino acid and glycomacropeptide medical foods in adolescents and adults with phenylketonuria; and 2) This is the first evidence of similar standardized neuropsychological testing data in adolescents and adults with early-treated phenylketonuria who consumed amino acid and glycomacropeptide medical foods.</p></abstract><kwd-group id="keys0005"><title>Keywords</title><kwd>Tyrosine</kwd><kwd>Leucine</kwd><kwd>Arginine</kwd><kwd>Executive function</kwd><kwd>Delis-Kaplan Executive Function System</kwd><kwd>Cambridge Neuropsychological Test Automated Battery</kwd></kwd-group></article-meta></front><body><p><bold>Specifications Table</bold><table-wrap id="t0020" position="float"><alt-text id="at0025">Table</alt-text><table frame="hsides" rules="groups"><tbody><tr><td>Subject area</td><td><italic>Biology, Medicine</italic></td></tr><tr><td>More specific subject area</td><td><italic>Inherited Metabolic Disorders</italic></td></tr><tr><td>Type of data</td><td><italic>Figure (study design), Tables (dietary amino acid intakes, neuropsychological testing outcomes)</italic></td></tr><tr><td>How data was acquired</td><td><italic>Assessment of dietary intake of amino acids and neuropsychological function in patients with PKU</italic></td></tr><tr><td>Data format</td><td><italic>Analyzed data, mean&#x000b1;SD, median (25th&#x02013;75th percentile)</italic></td></tr><tr><td>Experimental factors</td><td><italic>Data of subjects with PKU enrolled in Clinical trial at Waisman center, Madison, WI and Boston Children&#x005f3;s hospital, Boston, MA.</italic></td></tr><tr><td>Experimental features</td><td><italic>Randomized Crossover Clinical Trial</italic></td></tr><tr><td>Data source location</td><td><italic>Madison, Wisconsin, USA</italic></td></tr><tr><td>Data accessibility</td><td><italic>The data are accessible within the article</italic></td></tr></tbody></table></table-wrap></p><p><bold>Value of the data</bold><list list-type="simple"><list-item id="u0005"><label>&#x02022;</label><p>The data presented are the first comparison of how ingestion of medical foods comprised primarily of single amino acids or intact protein from glycomacropeptide (a 64-amino acid glycophosphopeptide isolated from cheese whey) affect the dietary intake profile of amino acids.</p></list-item><list-item id="u0010"><label>&#x02022;</label><p>The dietary intake of 18 amino acids provides useful information to clinicians and researchers related to typical amino acid intake of individuals with phenylketonuria.</p></list-item><list-item id="u0015"><label>&#x02022;</label><p>The data from the standardized neuropsychological tests can be compared with pharmacological studies using these same tests to contrast the effectiveness of dietary management with pharmacological treatment in subjects with phenylketonuria <xref rid="bib3" ref-type="bibr">[3]</xref>, <xref rid="bib4" ref-type="bibr">[4]</xref>.</p></list-item><list-item id="u0020"><label>&#x02022;</label><p>These data are useful to clinicians and researchers evaluating the safety and efficacy of glycomacropeptide medical foods in the nutritional management of phenylketonuria.</p></list-item></list></p><sec id="s0005"><label>1</label><title>Data</title><p>Summary data for dietary intake of amino acids and assessment of neuropsychological and executive function are presented for subjects with phenylketonuria enrolled in a randomized, controlled, crossover trial conducted from November 2010 to July 2015 <xref rid="bib1" ref-type="bibr">[1]</xref>, <xref rid="bib2" ref-type="bibr">[2]</xref>. These data are herein reported for the first time (<xref rid="t0005" ref-type="table">Table 1</xref>, <xref rid="t0010" ref-type="table">Table 2</xref>, <xref rid="t0015" ref-type="table">Table 3</xref>). The trial is registered at www.clinicaltrials.gov as NCT01428258 .<table-wrap id="t0005" position="float"><label>Table 1</label><caption><p>Daily dietary intake profile of 18 amino acids of the low-phenylalanine diet in combination with amino acid medical foods and glycomacropeptide medical foods in participants with classical and variant phenylketonuria.</p></caption><alt-text id="at0010">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th><bold>Amino acids</bold></th><th colspan="4"><bold>Dietary treatment</bold><xref rid="tbl1fna" ref-type="table-fn">a</xref><xref rid="tbl1fnb" ref-type="table-fn">,b</xref><hr/></th><th colspan="4" align="left"><bold>PKU Genotype</bold><xref rid="tbl1fne" ref-type="table-fn">e</xref><hr/></th><th colspan="3"><bold>p-values</bold><hr/></th></tr><tr><th/><th colspan="2"><bold>AA-MF</bold><xref rid="tbl1fnc" ref-type="table-fn">c</xref></th><th colspan="2" align="left"><bold>GMP-MF</bold><xref rid="tbl1fnd" ref-type="table-fn">d</xref></th><th colspan="2" align="left"><bold>Classical</bold></th><th colspan="2" align="left"><bold>Variant</bold></th><th><bold>trt</bold></th><th><bold>gt</bold></th><th><bold>trt &#x000d7; gt</bold></th></tr></thead><tbody><tr><td><bold>Alanine</bold></td><td/><td/><td align="right"/><td/><td align="right"/><td/><td align="right"/><td/><td/><td/><td/></tr><tr><td>&#x000a0;g Ala/d</td><td align="right">4.0</td><td>(2.9&#x02013;5.0)</td><td align="right">3.3</td><td>(2.6&#x02013;3.5)</td><td align="right">3.5</td><td>(2.9&#x02013;4.3)</td><td align="right">3.3</td><td>(2.7&#x02013;4.0)</td><td>0.002</td><td>0.56</td><td>0.39</td></tr><tr><td>&#x000a0;&#x000a0;g Ala from MF/d</td><td align="right">3.4</td><td>(2.0&#x02013;4.0)</td><td align="right">2.2</td><td>(1.7&#x02013;2.8)</td><td align="right">2.7</td><td>(2.0&#x02013;3.7)</td><td align="right">2.0</td><td>(1.6&#x02013;2.9)</td><td>0.001</td><td>0.15</td><td>0.23</td></tr><tr><td>&#x000a0;&#x000a0;g Ala from NF/d</td><td align="right">0.7</td><td>(0.6&#x02013;1.1)</td><td align="right">0.8</td><td>(0.6&#x02013;1.3)</td><td align="right">0.7</td><td>(0.5&#x02013;1.1)</td><td align="right">1.0</td><td>(0.7&#x02013;1.7)</td><td>0.81</td><td>0.07</td><td>0.38</td></tr><tr><td><bold>Arginine</bold></td><td align="right"/><td/><td align="right"/><td/><td align="right"/><td/><td align="right"/><td/><td/><td/><td/></tr><tr><td>&#x000a0;g Arg/d</td><td align="right">5.1</td><td>(4.3&#x02013;6.7)</td><td align="right">6.0</td><td>(5.3&#x02013;7.3)</td><td align="right">6.0</td><td>(4.8&#x02013;7.2)</td><td align="right">5.6</td><td>(4.1&#x02013;7.0)</td><td>0.01</td><td>0.59</td><td>0.45</td></tr><tr><td>&#x000a0;&#x000a0;g Arg from MF/d</td><td align="right">4.2</td><td>(2.9&#x02013;5.5)</td><td align="right">4.9</td><td>(4.0&#x02013;6.5)</td><td align="right">4.9</td><td>(3.8&#x02013;6.1)</td><td align="right">4.1</td><td>(2.9&#x02013;5.8)</td><td>0.01</td><td>0.31</td><td>0.30</td></tr><tr><td>&#x000a0;&#x000a0;g Arg from NF/d</td><td align="right">0.9</td><td>(0.7&#x02013;1.3)</td><td align="right">0.9</td><td>(0.6&#x02013;1.6)</td><td align="right">0.8</td><td>(0.6&#x02013;1.3)</td><td align="right">1.1</td><td>(0.8&#x02013;2.0)</td><td>0.93</td><td>0.13</td><td>0.52</td></tr><tr><td><bold>Aspartate</bold></td><td align="right"/><td/><td align="right"/><td/><td align="right"/><td/><td align="right"/><td/><td/><td/><td/></tr><tr><td>&#x000a0;g Asp/d<xref rid="tbl1fnf" ref-type="table-fn">f</xref></td><td align="right">6.3</td><td>(5.2&#x02013;7.4)</td><td align="right">5.3</td><td>(4.7&#x02013;6.0)</td><td align="right">5.8</td><td>(5.0&#x02013;7.1)</td><td align="right">5.3</td><td>(4.2&#x02013;6.5)</td><td>0.01</td><td>0.23</td><td>&#x02013;</td></tr><tr><td>&#x000a0;&#x000a0;g Asp from MF/d</td><td align="right">4.7</td><td>(2.8&#x02013;5.9)</td><td align="right">3.2</td><td>(2.4&#x02013;4.0)</td><td align="right">4.1</td><td>(2.9&#x02013;5.3)</td><td align="right">2.7</td><td>(2.1&#x02013;3.8)</td><td>0.01</td><td>0.08</td><td>0.11</td></tr><tr><td>&#x000a0;&#x000a0;g Asp from NF/d</td><td align="right">1.7</td><td>(1.4&#x02013;2.9)</td><td align="right">1.9</td><td>(1.3&#x02013;2.7)</td><td align="right">1.6</td><td>(1.3&#x02013;2.6)</td><td align="right">2.0</td><td>(1.6&#x02013;3.7)</td><td>0.74</td><td>0.18</td><td>0.68</td></tr><tr><td><bold>Cysteine</bold></td><td align="right"/><td/><td align="right"/><td/><td align="right"/><td/><td align="right"/><td/><td/><td/><td/></tr><tr><td>&#x000a0;Cys/d</td><td align="right">3.0</td><td>(2.5&#x02013;3.5)</td><td align="right">0.6</td><td>(0.4&#x02013;0.8)</td><td align="right">1.5</td><td>(0.6&#x02013;3.0)</td><td align="right">1.5</td><td>(0.6&#x02013;3.0)</td><td>&#x0003c;0.0001</td><td>0.52</td><td>0.12</td></tr><tr><td>&#x000a0;&#x000a0;g Cys from MF/d<xref rid="tbl1fnf" ref-type="table-fn">f</xref></td><td align="right">2.2</td><td>(1.9&#x02013;3.0)</td><td align="right">0.01</td><td>(0&#x02013;0.03)</td><td align="right">0.4</td><td>(0.01&#x02013;2.4)</td><td align="right">0.4</td><td>(0.02&#x02013;2.1)</td><td>&#x0003c;0.0001</td><td>0.87</td><td>&#x02013;</td></tr><tr><td>&#x000a0;&#x000a0;g Cys from NF/d</td><td align="right">0.6</td><td>(0.4&#x02013;0.8)</td><td align="right">0.6</td><td>(0.4&#x02013;0.8)</td><td align="right">0.5</td><td>(0.4&#x02013;0.7)</td><td align="right">0.7</td><td>(0.5&#x02013;1.3)</td><td>0.75</td><td>0.10</td><td>0.64</td></tr><tr><td><bold>Glutamate</bold></td><td align="right"/><td/><td align="right"/><td/><td align="right"/><td/><td align="right"/><td/><td/><td/><td/></tr><tr><td>&#x000a0;g Glu/d</td><td align="right">7.1</td><td>(4.2&#x02013;13.5)</td><td align="right">12.1</td><td>(9.9&#x02013;15.0)</td><td align="right">11.5</td><td>(7.5&#x02013;14.7)</td><td align="right">10.2</td><td>(5.9&#x02013;12.7)</td><td>0.0003</td><td>0.64</td><td>0.10</td></tr><tr><td>&#x000a0;&#x000a0;g Glu from MF/d</td><td align="right">0.6</td><td>(0&#x02013;9.1)</td><td align="right">7.2</td><td>(5.6&#x02013;8.9)</td><td align="right">7.2</td><td>(2.7&#x02013;9.5)</td><td align="right">3.9</td><td>(0&#x02013;7.0)</td><td>0.0002</td><td>0.07</td><td>0.07</td></tr><tr><td>&#x000a0;&#x000a0;g Glu from NF/d</td><td align="right">4.1</td><td>(2.9&#x02013;5.5)</td><td align="right">4.8</td><td>(3.0&#x02013;6.2)</td><td align="right">3.8</td><td>(2.7&#x02013;5.5)</td><td align="right">5.1</td><td>(3.1&#x02013;8.2)</td><td>0.91</td><td>0.16</td><td>0.83</td></tr><tr><td><bold>Glycine</bold></td><td align="right"/><td/><td align="right"/><td/><td align="right"/><td/><td align="right"/><td/><td/><td/><td/></tr><tr><td>&#x000a0;g Gly/d</td><td align="right">4.0</td><td>(3.4&#x02013;5.8)</td><td align="right">1.1</td><td>(0.9&#x02013;1.4)</td><td align="right">2.3</td><td>(1.1&#x02013;4.2)</td><td align="right">2.8</td><td>(1.1&#x02013;3.7)</td><td>&#x0003c;0.0001</td><td>0.74</td><td>0.51</td></tr><tr><td>&#x000a0;&#x000a0;g Gly from MF/d</td><td align="right">3.3</td><td>(2.6&#x02013;4.9)</td><td align="right">0.4</td><td>(0.3&#x02013;0.5)</td><td align="right">1.0</td><td>(0.4&#x02013;3.7)</td><td align="right">1.0</td><td>(0.4&#x02013;3.0)</td><td>&#x0003c;0.0001</td><td>0.44</td><td>0.57</td></tr><tr><td>&#x000a0;&#x000a0;g Gly from NF/d</td><td align="right">0.6</td><td>(0.5&#x02013;0.9)</td><td align="right">0.7</td><td>(0.5&#x02013;1.0)</td><td align="right">0.6</td><td>(0.5&#x02013;0.8)</td><td align="right">0.8</td><td>(0.6&#x02013;1.6)</td><td>0.82</td><td>0.11</td><td>0.28</td></tr><tr><td><bold>Histidine</bold></td><td align="right"/><td/><td align="right"/><td/><td align="right"/><td/><td align="right"/><td/><td/><td/><td/></tr><tr><td>&#x000a0;g His/d</td><td align="right">2.4</td><td>(2.1&#x02013;2.7)</td><td align="right">2.0</td><td>(1.5&#x02013;2.1)</td><td align="right">2.2</td><td>(1.8&#x02013;2.6)</td><td align="right">2.1</td><td>(1.6&#x02013;2.4)</td><td>0.002</td><td>0.73</td><td>0.55</td></tr><tr><td>&#x000a0;&#x000a0;g His from MF/d</td><td align="right">1.8</td><td>(1.5&#x02013;2.3)</td><td align="right">1.3</td><td>(1.0&#x02013;1.7)</td><td align="right">1.8</td><td>(1.3&#x02013;2.1)</td><td align="right">1.4</td><td>(1.0&#x02013;1.7)</td><td>&#x0003c;0.0001</td><td>0.11</td><td>0.39</td></tr><tr><td>&#x000a0;&#x000a0;g His from NF/d</td><td align="right">0.4</td><td>(0.3&#x02013;0.6)</td><td align="right">0.5</td><td>(0.3&#x02013;0.7)</td><td align="right">0.4</td><td>(0.3&#x02013;0.6)</td><td align="right">0.6</td><td>(0.4&#x02013;2.0)</td><td>0.63</td><td>0.09</td><td>0.81</td></tr><tr><td><bold>Isoleucine</bold></td><td align="right"/><td/><td align="right"/><td/><td align="right"/><td/><td align="right"/><td/><td/><td/><td/></tr><tr><td>&#x000a0;g Ile/d</td><td align="right">4.1</td><td>(3.7&#x02013;5.3)</td><td align="right">5.0</td><td>(3.6&#x02013;5.6)</td><td align="right">4.8</td><td>(3.9&#x02013;5.6)</td><td align="right">4.0</td><td>(3.6&#x02013;5.3)</td><td>0.09</td><td>0.26</td><td>0.17</td></tr><tr><td>&#x000a0;&#x000a0;g Ile from MF/d</td><td align="right">3.4</td><td>(2.8&#x02013;4.0)</td><td align="right">3.8</td><td>(2.9&#x02013;4.9)</td><td align="right">3.8</td><td>(3.2&#x02013;5.0)</td><td align="right">2.9</td><td>(2.5&#x02013;3.7)</td><td>0.16</td><td>0.08</td><td>0.15</td></tr><tr><td>&#x000a0;&#x000a0;g Ile from NF/d</td><td align="right">0.7</td><td>(0.5&#x02013;1.0)</td><td align="right">0.8</td><td>(0.5&#x02013;1.2)</td><td align="right">0.6</td><td>(0.5&#x02013;1.0)</td><td align="right">1.1</td><td>(0.6&#x02013;1.6)</td><td>0.61</td><td>0.07</td><td>0.77</td></tr><tr><td><bold>Leucine</bold></td><td align="right"/><td/><td align="right"/><td/><td align="right"/><td/><td align="right"/><td/><td/><td/><td/></tr><tr><td>&#x000a0;g Leu/d</td><td align="right">7.4</td><td>(6.4&#x02013;9.2)</td><td align="right">12.5</td><td>(9.9&#x02013;14.8)</td><td align="right">10.2</td><td>(8.0&#x02013;13.0)</td><td align="right">7.8</td><td>(6.5&#x02013;12.1)</td><td>&#x0003c;0.0001</td><td>0.34</td><td>0.21</td></tr><tr><td>&#x000a0;&#x000a0;g Leu from MF/d</td><td align="right">6.3</td><td>(4.4&#x02013;7.5)</td><td align="right">10.4</td><td>(8.7&#x02013;13.3)</td><td align="right">8.8</td><td>(6.3&#x02013;10.9)</td><td align="right">6.3</td><td>(4.8&#x02013;9.6)</td><td>&#x0003c;0.0001</td><td>0.15</td><td>0.18</td></tr><tr><td>&#x000a0;&#x000a0;g Leu from NF/d</td><td align="right">1.3</td><td>(1.0&#x02013;1.8)</td><td align="right">1.5</td><td>(0.9&#x02013;2.7)</td><td align="right">1.2</td><td>(0.9&#x02013;1.8)</td><td align="right">1.9</td><td>(1.1&#x02013;3.0)</td><td>0.59</td><td>0.07</td><td>0.68</td></tr><tr><td><bold>Lysine</bold></td><td align="right"/><td/><td align="right"/><td/><td align="right"/><td/><td align="right"/><td/><td/><td/><td/></tr><tr><td>&#x000a0;g Lys/d</td><td align="right">5.5</td><td>(4.4&#x02013;6.6)</td><td align="right">3.2</td><td>(3.0&#x02013;3.7)</td><td align="right">4.0</td><td>(3.2&#x02013;5.9)</td><td align="right">4.1</td><td>(3.3&#x02013;5.1)</td><td>&#x0003c;0.0001</td><td>0.84</td><td>0.05</td></tr><tr><td>&#x000a0;&#x000a0;g Lys from MF/d</td><td align="right">4.8</td><td>(3.2&#x02013;5.1)</td><td align="right">2.2</td><td>(1.8&#x02013;2.8)</td><td align="right">3.0</td><td>(2.2&#x02013;4.9)</td><td align="right">2.6</td><td>(2.0&#x02013;3.3)</td><td>&#x0003c;0.0001</td><td>0.06</td><td>0.01</td></tr><tr><td>&#x000a0;&#x000a0;g Lys from NF/d</td><td align="right">0.7</td><td>(0.5&#x02013;1.2)</td><td align="right">0.9</td><td>(0.6&#x02013;1.5)</td><td align="right">0.7</td><td>(0.5&#x02013;1.1)</td><td align="right">1.3</td><td>(0.7&#x02013;2.0)</td><td>0.68</td><td>0.049</td><td>0.94</td></tr><tr><td><bold>Methionine</bold></td><td align="right"/><td/><td align="right"/><td/><td align="right"/><td/><td align="right"/><td/><td/><td/><td/></tr><tr><td>&#x000a0;g Met/d</td><td align="right">1.5</td><td>(1.2&#x02013;2.1)</td><td align="right">1.2</td><td>(1.0&#x02013;1.5)</td><td align="right">1.4</td><td>(1.1&#x02013;1.7)</td><td align="right">1.3</td><td>(1.1&#x02013;1.7)</td><td>0.004</td><td>0.60</td><td>0.34</td></tr><tr><td>&#x000a0;&#x000a0;g Met from MF/d</td><td align="right">1.0</td><td>(0.8&#x02013;1.6)</td><td align="right">0.7</td><td>(0.5&#x02013;1.0)</td><td align="right">1.0</td><td>(0.8&#x02013;1.3)</td><td align="right">0.7</td><td>(0.5&#x02013;0.9)</td><td>0.0001</td><td>0.04</td><td>0.07</td></tr><tr><td>&#x000a0;&#x000a0;g Met from NF/d</td><td align="right">0.4</td><td>(0.2&#x02013;0.5)</td><td align="right">0.4</td><td>(0.2&#x02013;0.7)</td><td align="right">0.3</td><td>(0.2&#x02013;0.5)</td><td align="right">0.5</td><td>(0.3&#x02013;0.9)</td><td>0.63</td><td>0.09</td><td>0.54</td></tr><tr><td><bold>Phenylalanine</bold></td><td align="right"/><td/><td align="right"/><td/><td align="right"/><td/><td align="right"/><td/><td/><td/><td/></tr><tr><td>&#x000a0;mg Phe/d</td><td align="right">924</td><td>(663-1,187)</td><td align="right">1,014</td><td>(707-1,433)</td><td align="right">855</td><td>(569-1,180)</td><td align="right">1,082</td><td>(814-1,973)</td><td>0.25</td><td>0.06</td><td>0.75</td></tr><tr><td>&#x000a0;&#x000a0;mg Phe from MF/d</td><td align="right">0</td><td>(0-0)</td><td align="right">85</td><td>(70&#x02013;110)</td><td align="right">4</td><td>(0&#x02013;92)</td><td align="right">25</td><td>(0&#x02013;80)</td><td>&#x0003c;0.0001</td><td>0.73</td><td>&#x02013;</td></tr><tr><td>&#x000a0;&#x000a0;mg Phe from NF/d</td><td align="right">924</td><td>(663-1,187)</td><td align="right">929</td><td>(640-1,383)</td><td align="right">797</td><td>(544-1,167)</td><td align="right">1,065</td><td>(734-1,973)</td><td>0.97</td><td>0.07</td><td>0.92</td></tr><tr><td><bold>Proline</bold></td><td align="right"/><td/><td align="right"/><td/><td align="right"/><td/><td align="right"/><td/><td/><td/><td/></tr><tr><td>&#x000a0;g Pro/d</td><td align="right">5.9</td><td>(5.2&#x02013;6.7)</td><td align="right">6.3</td><td>(5.1&#x02013;7.5)</td><td align="right">6.3</td><td>(5.3&#x02013;6.9)</td><td align="right">5.5</td><td>(4.9&#x02013;7.0)</td><td>0.28</td><td>0.85</td><td>0.25</td></tr><tr><td>&#x000a0;&#x000a0;g Pro from MF/d</td><td align="right">4.3</td><td>(3.3&#x02013;5.9)</td><td align="right">4.5</td><td>(3.6&#x02013;5.7)</td><td align="right">4.6</td><td>(3.9&#x02013;5.8)</td><td align="right">3.9</td><td>(3.1&#x02013;4.6)</td><td>0.88</td><td>0.20</td><td>0.26</td></tr><tr><td>&#x000a0;&#x000a0;g Pro from NF/d</td><td align="right">1.2</td><td>(0.8&#x02013;1.9)</td><td align="right">1.6</td><td>(0.9&#x02013;2.2)</td><td align="right">1.1</td><td>(0.7&#x02013;1.8)</td><td align="right">1.8</td><td>(0.9&#x02013;2.5)</td><td>0.36</td><td>0.12</td><td>0.91</td></tr><tr><td><bold>Serine</bold></td><td align="right"/><td/><td align="right"/><td/><td align="right"/><td/><td align="right"/><td/><td/><td/><td/></tr><tr><td>&#x000a0;g Ser/d</td><td align="right">3.7</td><td>(3.1&#x02013;4.7)</td><td align="right">3.8</td><td>(3.0&#x02013;4.2)</td><td align="right">3.8</td><td>(3.2&#x02013;4.5)</td><td align="right">3.5</td><td>(3.0&#x02013;4.3)</td><td>0.28</td><td>0.59</td><td>0.86</td></tr><tr><td>&#x000a0;&#x000a0;g Ser from MF/d</td><td align="right">2.7</td><td>(2.0&#x02013;3.5)</td><td align="right">2.5</td><td>(1.8&#x02013;3.1)</td><td align="right">2.9</td><td>(2.1&#x02013;3.6)</td><td align="right">2.2</td><td>(1.7&#x02013;2.7)</td><td>0.13</td><td>0.15</td><td>0.74</td></tr><tr><td>&#x000a0;&#x000a0;g Ser from NF/d</td><td align="right">0.8</td><td>(0.6&#x02013;1.1)</td><td align="right">0.9</td><td>(0.5&#x02013;1.3)</td><td align="right">0.7</td><td>(0.5&#x02013;1.1)</td><td align="right">1.1</td><td>(0.8&#x02013;1.8)</td><td>0.72</td><td>0.10</td><td>0.79</td></tr><tr><td><bold>Threonine</bold></td><td align="right"/><td/><td align="right"/><td/><td align="right"/><td/><td align="right"/><td/><td/><td/><td/></tr><tr><td>&#x000a0;g Thr/d</td><td align="right">3.5</td><td>(3.1&#x02013;4.4)</td><td align="right">7.0</td><td>(5.3&#x02013;8.0)</td><td align="right">5.0</td><td>(3.6&#x02013;7.0)</td><td align="right">4.3</td><td>(3.4&#x02013;6.5)</td><td>&#x0003c;0.0001</td><td>0.37</td><td>0.53</td></tr><tr><td>&#x000a0;&#x000a0;g Thr from MF/d</td><td align="right">3.0</td><td>(2.2&#x02013;3.3)</td><td align="right">5.8</td><td>(4.6&#x02013;7.3)</td><td align="right">4.1</td><td>(3.0&#x02013;6.0)</td><td align="right">3.2</td><td>(2.2&#x02013;5.2)</td><td>&#x0003c;0.0001</td><td>0.18</td><td>0.45</td></tr><tr><td>&#x000a0;&#x000a0;g Thr from NF/d</td><td align="right">0.6</td><td>(0.5&#x02013;0.9)</td><td align="right">0.7</td><td>(0.5&#x02013;1.1)</td><td align="right">0.6</td><td>(0.5&#x02013;0.9)</td><td align="right">0.9</td><td>(0.6&#x02013;1.4)</td><td>0.68</td><td>0.10</td><td>0.55</td></tr><tr><td><bold>Tryptophan</bold></td><td align="right"/><td/><td align="right"/><td/><td align="right"/><td/><td align="right"/><td/><td/><td/><td/></tr><tr><td>&#x000a0;g Trp/d<xref rid="tbl1fnf" ref-type="table-fn">f</xref></td><td align="right">1.4</td><td>(1.2&#x02013;1.8)</td><td align="right">1.1</td><td>(0.9&#x02013;1.2)</td><td align="right">1.2</td><td>(1.0&#x02013;1.5)</td><td align="right">1.2</td><td>(1.0&#x02013;1.3)</td><td>0.0006</td><td>0.35</td><td>&#x02013;</td></tr><tr><td>&#x000a0;&#x000a0;g Trp from MF/d</td><td align="right">1.2</td><td>(0.9&#x02013;1.4)</td><td align="right">0.8</td><td>(0.6&#x02013;0.9)</td><td align="right">1.0</td><td>(0.8&#x02013;1.3)</td><td align="right">0.8</td><td>(0.6&#x02013;1.0)</td><td>&#x0003c;0.0001</td><td>0.10</td><td>0.03</td></tr><tr><td>&#x000a0;&#x000a0;g Trp from NF/d</td><td align="right">0.2</td><td>(0.2&#x02013;0.3)</td><td align="right">0.2</td><td>(0.1&#x02013;0.4)</td><td align="right">0.2</td><td>(0.1&#x02013;0.3)</td><td align="right">0.3</td><td>(0.2&#x02013;0.5)</td><td>0.81</td><td>0.22</td><td>0.87</td></tr><tr><td><bold>Tyrosine</bold></td><td align="right"/><td/><td align="right"/><td/><td align="right"/><td/><td align="right"/><td/><td/><td/><td/></tr><tr><td>&#x000a0;g Tyr/d</td><td align="right">6.1</td><td>(5.1&#x02013;7.8)</td><td align="right">5.2</td><td>(3.4&#x02013;6.2)</td><td align="right">6.0</td><td>(4.5&#x02013;7.7)</td><td align="right">5.1</td><td>(3.9&#x02013;6.1)</td><td>0.0004</td><td>0.21</td><td>0.07</td></tr><tr><td>&#x000a0;&#x000a0;g Tyr from MF/d</td><td align="right">5.6</td><td>(4.0&#x02013;7.3)</td><td align="right">3.8</td><td>(2.3&#x02013;5.2)</td><td align="right">5.3</td><td>(3.8&#x02013;6.4)</td><td align="right">3.9</td><td>(3.1&#x02013;5.0)</td><td>0.0003</td><td>0.11</td><td>0.08</td></tr><tr><td>&#x000a0;&#x000a0;g Tyr from NF/d<xref rid="tbl1fnf" ref-type="table-fn">f</xref></td><td align="right">0.7</td><td>(0.4&#x02013;1.0)</td><td align="right">0.6</td><td>(0.4&#x02013;1.2)</td><td align="right">0.6</td><td>(0.4&#x02013;0.8)</td><td align="right">0.9</td><td>(0.5&#x02013;1.4)</td><td>0.81</td><td>0.02</td><td>&#x02013;</td></tr><tr><td><bold>Valine</bold></td><td align="right"/><td/><td align="right"/><td/><td align="right"/><td/><td align="right"/><td/><td/><td/><td/></tr><tr><td>&#x000a0;g Val/d</td><td align="right">4.9</td><td>(4.3&#x02013;6.2)</td><td align="right">4.6</td><td>(3.5&#x02013;5.0)</td><td align="right">4.8</td><td>(4.2&#x02013;5.9)</td><td align="right">4.5</td><td>(4.0&#x02013;5.0)</td><td>0.03</td><td>0.29</td><td>0.07</td></tr><tr><td>&#x000a0;&#x000a0;g Val from MF/d</td><td align="right">4.1</td><td>(3.1&#x02013;4.8)</td><td align="right">3.3</td><td>(2.6&#x02013;4.2)</td><td align="right">4.1</td><td>(3.1&#x02013;4.8)</td><td align="right">3.0</td><td>(2.6&#x02013;4.0)</td><td>0.002</td><td>0.07</td><td>0.04</td></tr><tr><td>&#x000a0;&#x000a0;g Val from NF/d</td><td align="right">0.9</td><td>(0.6&#x02013;1.3)</td><td align="right">1.0</td><td>(0.7&#x02013;1.4)</td><td align="right">0.8</td><td>(0.6&#x02013;1.3)</td><td align="right">1.2</td><td>(0.8&#x02013;2.0)</td><td>0.68</td><td>0.08</td><td>0.71</td></tr></tbody></table><table-wrap-foot><fn id="sp0015"><p>AA-MF, amino acid medical food; GMP-MF, glycomacropeptide medical food; MF, medical foods; NF, natural foods; PKU, phenylketonuria.</p></fn><fn id="sp0020"><p>Values are medians with the 25th to 75th percentile values in parentheses, based on consecutive 3-d food records at the end of the 3-wk AA-MF and GMP-MF treatments, <italic>n</italic>=30. Statistical analysis included ANOVA with effects for treatment (trt, AA-MF or GMP-MF), genotype (gt, Classical or Variant PKU), and treatment by genotype interaction (trt &#x000d7; gt). When data was skewed, the Kruskal-Wallis test was used.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fna"><label>a</label><p id="ntp0005">Medical food was defined as any medical food intended for the treatment of PKU.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnb"><label>b</label><p id="ntp0010">Natural food was defined as any food or beverage that was not intended for the treatment of PKU.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnc"><label>c</label><p id="ntp0015">The AA-MFs consumed during the study (2010&#x02013;2015) included the following: CAMINO PRO PKU, Lophlex Power, Periflex Advance, Periflex Junior, Phenex-2, PhenylAde Essential Drink Mix, PhenylAde MTE Amino Acid Blend, Phenyl-Free 2, Phenyl-Free 2 HP, Phlexy-10 Drink Mix, Phlexy-10 Tablets, PKU Cooler 15, PKU Cooler 20, PKU Lophlex LQ 20, and XPhe Maxamum Powder.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnd"><label>d</label><p id="ntp0020">The Cambrooke Therapeutics GMP-MFs consumed during the study (2010&#x02013;2015) included the following: CaminoPro Pudding with Glytactin, Glytactin Bettermilk, Glytactin COMPLETE 15, Glytactin RESTORE, Glytactin RESTORE LITE, Glytactin RTD 15, and Glytactin SWIRL Caramel.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fne"><label>e</label><p id="ntp0025">Subjects classified with classical PKU have a genotype and lack of response to sapropterin dihydrochloride that are consistent with a severe PKU phenotype. Subjects classified with variant PKU have a phenylalanine hydroxylase genotype and/or response to sapropterin dihydrochloride that was consistent with a milder PKU phenotype. Mutation names are defined at <ext-link ext-link-type="uri" xlink:href="http://www.pahdb.mcgill.ca" id="ir0005">http://www.pahdb.mcgill.ca</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://www.biopku.org" id="ir0010">http://www.biopku.org</ext-link>.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnf"><label>f</label><p id="ntp0030">Kruskal-Wallis test was used.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t0010" position="float"><label>Table 2</label><caption><p>Group performance on Delis-Kaplan Executive Function System in subjects with phenylketonuria.</p></caption><alt-text id="at0015">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th/><th><bold>AA-MF</bold></th><th><bold>GMP-MF</bold></th><th/></tr><tr><th><bold>Delis-Kaplan Executive Function</bold></th><th><bold>Mean&#x000b1;SD</bold></th><th><bold>Mean&#x000b1;SD</bold></th><th><bold><italic>p</italic>-value</bold></th></tr><tr><th><bold>System categories</bold></th><th/><th/><th/></tr></thead><tbody><tr><td><bold>Verbal fluency</bold></td><td/><td/><td/></tr><tr><td>Letter fluency scaled</td><td>9.40&#x000b1;3.67</td><td>9.00&#x000b1;3.01</td><td>0.3462</td></tr><tr><td>Category fluency scaled</td><td>10.90&#x000b1;3.12</td><td>10.23&#x000b1;3.17</td><td>0.2231</td></tr><tr><td>Category switching scaled</td><td>9.66&#x000b1;2.68</td><td>9.63&#x000b1;3.59</td><td>0.7373</td></tr><tr><td>Category switching: total switching accuracy</td><td>10.45&#x000b1;2.44</td><td>10.10&#x000b1;3.14</td><td>0.3953</td></tr><tr><td>Letter fluency vs category fluency scaled</td><td>8.57&#x000b1;2.97</td><td>8.77&#x000b1;3.86</td><td>0.7486</td></tr><tr><td>Category switching vs category fluency scaled</td><td>8.97&#x000b1;3.29</td><td>9.43&#x000b1;3.70</td><td>0.4538</td></tr><tr><td>Category switching percent switching accuracy scaled</td><td>11.24&#x000b1;1.94</td><td>10.97&#x000b1;2.51</td><td>0.5118</td></tr><tr><td><bold>Design fluency</bold></td><td/><td/><td/></tr><tr><td>Filled dots</td><td>9.62&#x000b1;3.26</td><td>9.80&#x000b1;2.91</td><td>0.5548</td></tr><tr><td>Empty dots only</td><td>9.93&#x000b1;3.13</td><td>9.53&#x000b1;3.26</td><td>0.2947</td></tr><tr><td>Switching</td><td>10.21&#x000b1;2.53</td><td>10.27&#x000b1;2.69</td><td>0.838</td></tr><tr><td>Design fluency total correct: composite</td><td>10.31&#x000b1;3.30</td><td>10.27&#x000b1;3.36</td><td>0.9544</td></tr><tr><td>Combined filled+empty dots: composite</td><td>10.00&#x000b1;3.14</td><td>9.97&#x000b1;2.87</td><td>0.8965</td></tr><tr><td>Switching vs combined filled contrast</td><td>10.21&#x000b1;2.43</td><td>10.30&#x000b1;2.12</td><td>0.9384</td></tr><tr><td>Percent design accuracy scaled score</td><td>8.76&#x000b1;3.04</td><td>9.37&#x000b1;2.57</td><td>0.2537</td></tr></tbody></table><table-wrap-foot><fn id="sp0040"><p>Values are mean&#x000b1;SD compared with normative sample performance as reflected in</p></fn><fn id="sp0045"><p>scaled scores. Normative data, mean=10, SD=3, <italic>n</italic>=29&#x02013;30.</p></fn><fn id="sp0050"><p>AA-MF, amino acid medical foods; GMP-MF, glycomacropeptide medical foods.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t0015" position="float"><label>Table 3</label><caption><p>Group performance on Cambridge Neuropsychological Test Automated Battery in subjects with phenylketonuria.</p></caption><alt-text id="at0020">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th/><th><bold>AA-MF</bold></th><th><bold>GMP-MF</bold></th><th/></tr><tr><th><bold>Cambridge neuropsychological</bold></th><th rowspan="2"><bold>Mean&#x000b1;SD</bold></th><th rowspan="2"><bold>Mean&#x000b1;SD</bold></th><th rowspan="2"><bold><italic>p</italic>-value</bold></th></tr><tr><th><bold>test automated battery categories</bold></th></tr></thead><tbody><tr><td><bold>Stockings of Cambridge</bold></td><td/><td/><td/></tr><tr><td>SOC mean initial thinking</td><td>-0.113&#x000b1;1.26</td><td>0.184&#x000b1;0.81</td><td>0.127</td></tr><tr><td>SOC mean subsequent thinking</td><td>0.563&#x000b1;0.57</td><td>0.078&#x000b1;1.29</td><td>0.196</td></tr><tr><td>SOC problems solved in minimum moves</td><td>0.050&#x000b1;0.99</td><td>-0.52&#x000b1;1.02</td><td>0.172</td></tr><tr><td><bold>Spatial span</bold></td><td/><td/><td/></tr><tr><td>SSP length</td><td>0.389&#x000b1;1.29</td><td>0.201&#x000b1;1.08</td><td>0.441</td></tr><tr><td><bold>Spatial working memory</bold></td><td/><td/><td/></tr><tr><td>SWM between errors</td><td>0.278&#x000b1;1.22</td><td>0.014&#x000b1;0.97</td><td>0.087</td></tr><tr><td>SWM strategy</td><td>0.458&#x000b1;1.50</td><td>0.080&#x000b1;1.12</td><td>0.086</td></tr></tbody></table><table-wrap-foot><fn id="sp0060"><p>Values are Z-scores mean&#x000b1;SD, <italic>n</italic>=22&#x02013;24, Standard scores are</p></fn><fn id="sp0065"><p>mean=0, SD=1. Higher Z scores=better performance.</p></fn><fn id="sp0070"><p>AA-MF, amino acid medical foods; GMP-MF, glycomacropeptide medical foods.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="s0010"><label>2</label><title>Experimental design</title><p>Thirty subjects with early-treated phenylketonuria, 20 with classical and 10 with a milder or variant form of phenylketonuria, completed the clinical trial <xref rid="bib1" ref-type="bibr">[1]</xref>. The experimental design was a 2-stage, randomized, controlled, crossover trial where subjects followed their usual low-phenylalanine diet in combination with amino acid medical foods and glycomacropeptide medical foods for 3-weeks each at home (<xref rid="f0005" ref-type="fig">Fig. 1</xref>). The protocol included: a one-week baseline period for diet education and orientation to the protocol while consuming the usual amino acid medical foods, the first 3-week dietary treatment with glycomacropeptide medical foods or amino acid medical foods, a 3-week washout period with return to the usual amino acid medical foods, a 1-week baseline period, and lastly the second 3-week dietary treatment with the glycomacropeptide medical foods or amino acid medical foods.<fig id="f0005"><label>Fig. 1</label><caption><p>Experimental design.</p></caption><alt-text id="at0005">Fig. 1</alt-text><graphic xlink:href="gr1"/></fig></p></sec><sec id="s0015"><label>3</label><title>Materials and methods</title><p>Daily amino acid intake from the whole diet, medical foods, and natural food was calculated from consecutive 3-day food records at the end of the 3-week amino acid medical foods and glycomacropeptide medical foods treatments (<xref rid="t0005" ref-type="table">Table 1</xref>). Amino acid calculations were performed by a Registered Dietitian skilled in standardized diet entry using Food Processor SQL (ESHA, version 10.12.0).</p><p>Neuropsychological testing to assess executive function, the Delis-Kaplan Executive Function System&#x02122; (Pearson Canada Assessment, Inc. Ontario, Canada), and the Cambridge Neuropsychological Test Automated Battery (Cambridge Cognition Ltd, Cambridge, UK) was conducted by research staff trained in the administration of standard psychological assessments under the supervision of a licensed psychologist after following the amino acid medical foods and glycomacropeptide medical foods treatments for 3 weeks (<xref rid="t0010" ref-type="table">Table 2</xref>, <xref rid="t0015" ref-type="table">Table 3</xref>).</p></sec><sec id="s0020"><title>Funding</title><p>This work was supported by <funding-source id="gs1">Department of Health and Human Service</funding-source>s Grants R01 FD003711 from the FDA Office of Orphan Products Development to Ney, P30-HD-03352, T32 DK007665 to Ney, and by the Clinical and Translational Science Award (CTSA) program, through the NIH <funding-source id="gs2">National Center for Advancing Translational Sciences</funding-source> (NCATS), Grant UL1TR000427. Cambrooke Therapeutics, Inc. donated the glycomacropeptide medical foods used in this study.</p></sec></body><back><ref-list id="bibliog0005"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sbref1"><person-group person-group-type="author"><name><surname>Ney</surname><given-names>D.M.</given-names></name><name><surname>Stroup</surname><given-names>B.M.</given-names></name><name><surname>Clayton</surname><given-names>M.K.</given-names></name><name><surname>Murali</surname><given-names>S.G.</given-names></name><name><surname>Rice</surname><given-names>G.M.</given-names></name><name><surname>Rohr</surname><given-names>F.</given-names></name><name><surname>Levy</surname><given-names>H.L.</given-names></name></person-group><article-title>Glycomacropeptide for nutritional management of phenylketonuria: a randomized, controlled, crossover trial</article-title><source>Am. J. Clin. Nutr.</source><volume>104</volume><year>2016</year><fpage>334</fpage><lpage>345</lpage><pub-id pub-id-type="pmid">27413125</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sbref2"><person-group person-group-type="author"><name><surname>Ney</surname><given-names>D.M.</given-names></name><name><surname>Murali</surname><given-names>S.G.</given-names></name><name><surname>Stroup</surname><given-names>B.M.</given-names></name><name><surname>Nair</surname><given-names>N.</given-names></name><name><surname>Sawin</surname><given-names>E.A.</given-names></name><name><surname>Rohr</surname><given-names>F.</given-names></name><name><surname>Levy</surname><given-names>H.L.</given-names></name></person-group><article-title>Metabolomic changes demonstrate reduced bioavailability of tyrosine and altered metabolism of tryptophan via the kynurenine pathway with ingestion of medical foods in phenylketonuria</article-title><source>Mol. Genet. Metab.</source><year>2017</year></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sbref3"><person-group person-group-type="author"><name><surname>Schindeler</surname><given-names>S.</given-names></name><name><surname>Ghosh-Jerath</surname><given-names>S.</given-names></name><name><surname>Thompson</surname><given-names>S.</given-names></name><name><surname>Rocca</surname><given-names>A.</given-names></name><name><surname>Joy</surname><given-names>P.</given-names></name><name><surname>Kemp</surname><given-names>A.</given-names></name><name><surname>Rae</surname><given-names>C.</given-names></name><name><surname>Green</surname><given-names>K.</given-names></name><name><surname>Wilcken</surname><given-names>B.</given-names></name><name><surname>Chistodoulou</surname><given-names>J.</given-names></name></person-group><article-title>The effects of large neutral amino acid supplements in PKU: an MRS and neuropsychological study</article-title><source>Mol. Genet. Metab.</source><volume>91</volume><year>2007</year><fpage>48</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">17368065</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sbref4"><person-group person-group-type="author"><name><surname>van Spronsen</surname><given-names>F.J.</given-names></name><name><surname>Huijbregts</surname><given-names>S.C.</given-names></name><name><surname>Bosch</surname><given-names>A.M.</given-names></name><name><surname>Leuzzi</surname><given-names>V.</given-names></name></person-group><article-title>Cognitive, neurophysiological, and psychosocial outcomes in early-treated PKU-patients: a start toward standardized outcome measurement across development</article-title><source>Mol. Genet. Metab.</source><volume>104</volume><year>2011</year><fpage>S45</fpage><lpage>S51</lpage><pub-id pub-id-type="pmid">22018724</pub-id></element-citation></ref></ref-list><sec id="s0030" sec-type="supplementary-material"><label>Transparency document</label><title>Supplementary material</title><p><supplementary-material content-type="local-data" id="ec0005"><caption><p>Supplementary material</p></caption><media xlink:href="mmc1.pdf"/></supplementary-material>.</p></sec><fn-group><fn id="s0025" fn-type="supplementary-material"><label>Transparency document</label><p>Transparency data associated with this article can be found in the online version at <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.dib.2017.06.004" id="ir0015">10.1016/j.dib.2017.06.004</ext-link>.</p></fn></fn-group></back></article>